Induction of catalepsy in rats by NK1 receptor antagonist and early-life maternal separation synergistically: the involvement of CRF1 receptors

نویسندگان

1 دانشگاه محقق اردبیلی

2 دانشگاه ارومیه

3 دانشگاه ارومیه

4

5 دانشگاه گیلان

6

doi
10.32592/ajnpp.2024.11.2.103
چکیده

A lower level of brain substance P (SP) is detected in Parkinson’s disease; apparently, central SP-ergic deficiency takes place in Parkinsonian patients. The pathogenic relevance of this abnormality is unknown. Another understudied area is the influence of early-life adversities on Parkinsonism. Here, we hypothesized that i) simulation of central SP hypoactivity by intracerebral injections of NK1 receptor antagonist can initiate catalepsy, a model of Parkinsonian bradykinesia and rigidity, ii) early-life maternal separation (MS) can influence the SP-dependent catalepsy; and iii) the above catalepsy can be regulated by the blockade of CRF 1 receptors. The study was performed on Wistar rats. MS of pups was carried out at postnatal days 2-14 for 3 h per day. In adulthood (16-17 weeks of age), one hundred ninety-two males with MS history (weight 280-310 g) were examined behaviorally; catalepsy was assessed by a bar test. In undisturbed animals, i.c.v. administration of NK1 receptor antagonist L-733,060 at 10.0 ng produced clear catalepsy, the drug at the dose of 1.0 ng was ineffective. MS per se failed to exert catalepsy, however, in the MS-exposed rats, L-733,060 at 1.0 ng produced strong cataleptic response. Thus, the blocker of NK1 receptors and MS supra-additively initiated the development of catalepsy. This catalepsy was significantly reversed by NBI 35 965, an antagonist of CRF 1 receptors. Our findings show, for the first time, that the blockade of central NK1 receptors can induce catalepsy; this cataleptic response is synergistically potentiated by MS and is mediated by CRF 1 receptors. These data suggests that the combination of central NK1 receptor hypofunctioning and neonatal stress may dysregulate the extrapyramidal system. Apparently, the central processes mediated by NK1 and CRF 1 receptors might be potential therapeutic targets for Parkinsonism.